Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) received a $145.00 price objective from analysts at Credit Suisse Group AG in a research note issued to investors on Friday. The firm currently has a a “buy” rating on the biopharmaceutical company’s stock. Credit Suisse Group AG’s price objective points to a potential upside of 112.52% from the company’s current price.
Other equities research analysts have also recently issued research reports about the stock. Cowen and Company reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Sunday, June 12th. Leerink Swann reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Sunday, June 12th. Needham & Company LLC reissued a “buy” rating and set a $152.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday, July 25th. Zacks Investment Research raised shares of Alnylam Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, June 14th. Finally, JPMorgan Chase & Co. raised their price target on shares of Alnylam Pharmaceuticals from $80.00 to $83.00 and gave the stock an “overweight” rating in a report on Friday, August 5th. Three analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $110.14.
Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 68.23 on Friday. The company’s market cap is $5.85 billion. The company has a 50-day moving average of $73.16 and a 200 day moving average of $66.37. Alnylam Pharmaceuticals has a one year low of $49.96 and a one year high of $110.75.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.05) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.24) by $0.19. Alnylam Pharmaceuticals had a negative net margin of 1,204.91% and a negative return on equity of 29.60%. The company earned $8.70 million during the quarter, compared to analysts’ expectations of $8.09 million. During the same quarter in the prior year, the company posted ($0.85) earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was up .2% compared to the same quarter last year. Analysts anticipate that Alnylam Pharmaceuticals will post ($4.64) earnings per share for the current year.
In related news, CEO John Maraganore sold 30,151 shares of the firm’s stock in a transaction on Wednesday, July 20th. The shares were sold at an average price of $64.69, for a total transaction of $1,950,468.19. Following the sale, the chief executive officer now owns 148,465 shares in the company, valued at $9,604,200.85. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 4.00% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC purchased a new stake in Alnylam Pharmaceuticals during the second quarter valued at approximately $128,000. Seven Eight Capital LLC raised its stake in Alnylam Pharmaceuticals by 200.0% in the first quarter. Seven Eight Capital LLC now owns 2,700 shares of the biopharmaceutical company’s stock valued at $169,000 after buying an additional 1,800 shares in the last quarter. Meeder Asset Management Inc. purchased a new stake in Alnylam Pharmaceuticals during the second quarter valued at approximately $175,000. Bank of Montreal Can purchased a new stake in Alnylam Pharmaceuticals during the second quarter valued at approximately $193,000. Finally, BlueMountain Capital Management LLC raised its stake in Alnylam Pharmaceuticals by 89.3% in the first quarter. BlueMountain Capital Management LLC now owns 3,179 shares of the biopharmaceutical company’s stock valued at $200,000 after buying an additional 1,500 shares in the last quarter. Institutional investors own 85.96% of the company’s stock.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.